NCT06868004Completed
Holistic Nursing Benefits Cognitive and Psychiatric Symptoms in Alzheimer's Patients
Positive Impact of Holistic Nursing on Cognitive Impairment and Psychiatric Symptoms in Patients with Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 10 Mar 2025
Brief summary (registry, in English)
This clinical study aims to evaluate the effects of a holistic nursing (HN) intervention on cognitive function, psychological well-being, and overall health outcomes in patients with Alzheimer's disease (AD). AD is a progressive neurodegenerative disorder characterized by cognitive decline and behavioral changes, significantly impacting patients' quality of life and increasing the burden on caregivers. Conventional treatment primarily involves pharmacological interventions, but non-pharmacological approaches, such as specialized nursing care, have shown potential in improving patient outcomes. This study prospectively enrolled 105 AD patients admitted to our hospital between January 2023 and January 2024. Patients were divided into two groups based on admission periods: the control group (n=58) received standard care, while the observation group (n=47) received HN in addition to standard care. The HN intervention was implemented based on established guidelines for older adults with cognitive impairment and consisted of five key components: psychological support, cognitive stimulation, memory enhancement, self-care training, and environmental optimization. The study assessed cognitive function, psychiatric symptoms, anxiety, and depression levels before and after the intervention using validated scales, including the Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog), Montreal Cognitive Assessment (MoCA), and Self-rating Anxiety/Depression Scales (SAS/SDS). Additionally, blood biomarkers related to neurological function, such as dopamine, acetylcholine, serotonin, γ-aminobutyric acid, S100β, homocysteine, and interleukin-1β, were measured. Patient compliance, safety outcomes, and family satisfaction with the nursing intervention were also evaluated. The findings of this study may provide evidence supporting the integration of HN as a complementary approach in AD management, potentially improving cognitive function, reducing psychiatric symptoms, and enhancing overall patient well-being.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 105 (actual)
- First submitted
- 5 Mar 2025
- Start date
- 1 Jan 2023
- Primary completion date
- 31 Jan 2024
- Lead sponsor
- The First People's Hospital of Jingzhou
- Diseases
- Alzheimer disease
- NCT number
- NCT06868004
What you commit to
- Study type: Interventional
- Participants enrolled: 105
- From 1 Jan 2023 to the primary completion date, 31 Jan 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants who have received experimental treatments or clinical trials within the last 3 months.
Other illness
- History of intracranial surgery or major brain trauma.
- Coexisting psychiatric disorders or severe mental illnesses.
- Comorbid autoimmune diseases or severe malignancies.
- Individuals with a history of substance abuse or dependency.
- Participants with other medical conditions that, in the opinion of the investigator, would compromise participation in the study.
Other
- Significant visual, auditory, language, or motor impairments that would hinder participation in the study.
- Severe organ dysfunction that could interfere with study participation or safety.
- Pregnant or breastfeeding women.
Who the study is looking for
- Diagnosed with Alzheimer's Disease (AD) according to clinical and neuroimaging evidence.
- Aged between 60 to 80 years.
- Mild-to-moderate disease severity, with a Mini-Mental State Examination (MMSE) score ranging from 10 to 24.
- Adequate cognitive and functional capacity to complete questionnaires and follow the intervention protocol.
- Ability to communicate and comprehend instructions.
- Availability of comprehensive medical records.
- Informed consent obtained from the patient or their legal guardian.
Age in the registry: 60 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Jinzhou Medical University Coordinator of this site? Confirm its status | Jinzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.